Please login to the form below

Not currently logged in
Email:
Password:

kidney cancer

This page shows the latest kidney cancer news and features for those working in and with pharma, biotech and healthcare.

BMS unveils long-term results for Opdivo in kidney cancer

BMS unveils long-term results for Opdivo in kidney cancer

BMS is continuing to build the case for its checkpoint inhibitor Opdivo (nivolumab) in RCC – the most common type of kidney cancer – with updated results from two studies, as it begins ... RCC. BMS is facing increasing competition in kidney cancer,

Latest news

  • Roche files Tecentriq/Avastin combo in liver cancer Roche files Tecentriq/Avastin combo in liver cancer

    Levi Garraway. “Liver cancer is the most rapidly increasing cause of cancer-related death in the US. ... The Swiss pharma also had to withdraw a filing in Europe for Tecentriq/Avastin in renal cell carcinoma – a common form of kidney cancer – on

  • Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

    cancer as well as autoimmune indications, headed by a drug for solid tumours that is in a phase 1 trial. ... The modification extends the time the drug stays in the body compared to regular IL-2 or aldesleukin – which has been used for years to treat

  • Aveo’s tivozanib is knocked back by FDA once again Aveo’s tivozanib is knocked back by FDA once again

    Try as it might, Aveo Oncology just can’t persuade the FDA to accept a new regulatory filing for its kidney cancer candidate tivozanib.

  • Roche eyes filings for Tecentriq/Avastin combo in liver cancer Roche eyes filings for Tecentriq/Avastin combo in liver cancer

    Roche suffered a setback last year however when it decided to withdraw a filing in Europe for Tecentriq/Avastin in  renal cell carcinoma – a common form of kidney cancer – on the ... from other checkpoint inhibitors, and Roche is also eyeing other

  • MSD’s Keytruda catches up in kidney cancer MSD’s Keytruda catches up in kidney cancer

    common form of kidney cancer – advanced renal cell carcinoma (RCC). ... added. The kidney cancer market is now becoming increasingly competitive, with Keytruda and Opdivo also facing competition from Pfizer/Merck KGaA’s Bavencio (avelumab),  which

More from news
Approximately 23 fully matching, plus 129 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo ... up innate immune responses, and

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer); ... Additional revenues for

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... This protracted process is indicative of the now

  • Pharma investment in Indonesia Pharma investment in Indonesia

    Under this universal scheme, all healthcare services and drugs for major diseases, such as cancer, chronic kidney disease etc.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time ... This background will benefit Mirna, which has just

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • What are you doing, Dave?

    parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

  • A stumble, but not a fall – what’s next for Opdivo?

    and renal cell carcinoma (kidney cancer). ... Rubbing salt into BMS’s wounds, Merck's  Keytruda snagged a new FDA approval in head-and-neck cancer.

  • Immuno-oncology; bringing patients closer to treatment

    cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer. ... Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer.

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics